Role of D-chiro-inositol in the management of gestational diabetes mellitus: impact on maternal and fetal outcomes
https://doi.org/10.4081/wpph.2022.9507
Accepted: 29 June 2022
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Introduction. D-chiro-inositol (DCI) mediates insulin action and demonstrated a positive effect on metabolic parameters when administered in pregnant women with gestational diabetes mellitus (GDM). The aim of this study was to evaluate the impact of DCI supplementation in GDM patients on metabolic control and maternal and fetal outcomes.
Patients and methods. A cohort comprising 20 women with GDM was retrospectively evaluated; all the women were treated with a standard diet and half of them was given DCI. Several parameters (glycaemic control, total daily insulin dose, maternal and fetal biometric parameters) have been evaluated in all subjects and compared between the two groups (DCI vs control group).
Results. Women within the DCI group showed a tendency to a lower total daily insulin dose, better postprandial glucose values and lower birth weight. Given the small sample size, differences between the two groups were not statistically significant.
Conclusions. Supplementation with DCI in women with GDM is safe and, together with standard therapy, it seems to improve maternal metabolic parameters, in addition to exert a positive role in fetal development.
Johns EC, Denison FC, Norman JE, Reynolds RM. Gestational diabetes mellitus: mechanisms, treatment, and complications. Trends Endocrin Met 2018;29:743-54. DOI: https://doi.org/10.1016/j.tem.2018.09.004
Bonora E, Sesti G. Il diabete in italia. 1st ed., Bologna, Italy: Bononia University Press; 2016.
Bizzarri M, Fuso A, Dinicola S et al. Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease. Expert Opin Drug Metab Toxicol. 2016;12:1181-96. DOI: https://doi.org/10.1080/17425255.2016.1206887
Di Biase N, Martinelli M, Florio V et al. The effectiveness of D-chiro inositol treatment in gestational diabetes. Diabetes Case Rep 2017;2:131. DOI: https://doi.org/10.4172/2572-5629.1000131
Festa C, Succurro E, Fraticelli F et al. on behalf of AMD-SID Diabetes and Pregnancy Study Group. Position statement AMD-SID: integratori vitaminici, inositolo e probiotici nelle donne con iperglicemia avanzata. 2018. Available at: https://aemmedi.it/wp-content/uploads/2018/09/PS_Gruppo-Diabete-e-Gravidanza_Integratori-vitaminici-inositolo-e-probiotici-nelle-donne-con-iperglicemia-in-gravidanza.pdf
Manuale Free Style-Libre (Abbott GmbH, Wiesbaden, Germany). Available at: https://www.freestylelibre.it/content/dam/adc/fsl/images/it/it/restyling-2021/Manuale-FreeStyle-Libre.pdf
Manuale GlucoMen areo (A. Menarini Diagnostics, Firenze, Italy). Available at: http://www.areo.nu/images/nerladdaPdf/Areo2K_User_Manual_IT.pdf
Chiefari E, Arcidiacono B, Foti D, Brunetti A. Gestational diabetes mellitus: an updated overview. J Endocrinol Invest 2017;40:899-909. DOI: https://doi.org/10.1007/s40618-016-0607-5
Fraticelli F, Celentano C, Zecca IA et al. Effect of inositol stereoisomers at different dosages in gestational diabetes: an open-label, parallel, randomized controlled trial. Acta Diabetol 2018;55:805-12. DOI: https://doi.org/10.1007/s00592-018-1157-4
Supporting Agencies
NonePAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
